Health Catalyst anticipates $246M-$249M 2026 revenue following Vitalware divestiture (NASDAQ:HCAT)
· seekingalpha.com
Health Catalyst (HCAT) Q2 2026 earnings call: Vitalware divestiture, debt-free balance sheet, updated 2026 guidance, and migration churn risks—read now.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...